- Home
- AMLX vs IVA Comparison
AMLX vs IVA Comparison
Compare AMLX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- IVA
- Stock Information
- Founded
- AMLX 2014
- IVA 2011
- Country
- AMLX United States
- IVA France
- Employees
- AMLX N/A
- IVA N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- IVA Health Care
- Exchange
- AMLX Nasdaq
- IVA Nasdaq
- Market Cap
- AMLX 749.9M
- IVA 769.0M
- IPO Year
- AMLX 2022
- IVA 2020
- Fundamental
- Price
- AMLX $12.77
- IVA $5.28
- Analyst Decision
- AMLX Strong Buy
- IVA Strong Buy
- Analyst Count
- AMLX 7
- IVA 6
- Target Price
- AMLX $14.86
- IVA $15.33
- AVG Volume (30 Days)
- AMLX 2.0M
- IVA 74.0K
- Earning Date
- AMLX 11-06-2025
- IVA 09-26-2025
- Dividend Yield
- AMLX N/A
- IVA N/A
- EPS Growth
- AMLX N/A
- IVA N/A
- EPS
- AMLX N/A
- IVA N/A
- Revenue
- AMLX N/A
- IVA $14,591,573.00
- Revenue This Year
- AMLX N/A
- IVA $80.35
- Revenue Next Year
- AMLX N/A
- IVA N/A
- P/E Ratio
- AMLX N/A
- IVA N/A
- Revenue Growth
- AMLX N/A
- IVA N/A
- 52 Week Low
- AMLX $2.60
- IVA $1.53
- 52 Week High
- AMLX $13.07
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- AMLX 82.10
- IVA 54.95
- Support Level
- AMLX $11.42
- IVA $5.21
- Resistance Level
- AMLX $12.25
- IVA $5.78
- Average True Range (ATR)
- AMLX 0.59
- IVA 0.37
- MACD
- AMLX 0.21
- IVA -0.09
- Stochastic Oscillator
- AMLX 91.70
- IVA 9.56
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.